Thelma Therapeutics is on the verge of being delisted from the main bourse Kospi, and this might hurt its plan to manufacture CoviVac, a Russian Covid-19 vaccine, in a CMO deal, observers said.On Tuesday, the Korea Exchange said that Thelma Therapeutics met the criteria to be delisted from the stock
SK Bioscience said it would temporarily discontinue production of SKYCellflu, an influenza vaccine, to focus on manufacturing Covid-19 vaccines.Industry sources said Monday that SK Bioscience would not manufacture the flu vaccine SKYCellflu this year. The company said the move was to allocate its fu
The European Medicines Agency (EMA) on Friday recommended conditional approval of Celltrion's Covid-19 therapy Regkirona (ingredient: regdanvimab) for patients who do not require oxygen therapy and those with a high risk of worsening symptoms.The agency said that Regkirona could treat patients with
The Korea Disease Control and Prevention Agency (KDCA) said Thursday that it has confirmed in cell studies that GC Pharma’s plasma therapy is effective against the U.K. and South African Covid-19 variants.The agency analyzed the efficacy against nine virus genotypes -- S, L, V, G, GR, GH, and GV plu
LG Chem, Celltrion, and Samsung Bioepis said they have finished preparation to sell the biosimilars of Humira, an autoimmune disease treatment, in Japan, Europe, and Korea, respectively.On Tuesday, LG Chem said in a public filing that it obtained approval from Japan’s Health Ministry for Adalimumab
CHA Biotech said Tuesday that it has agreed to manufacture SCM Lifescience’s cell therapies using bone marrow.Under the accord, CHA Biotech will make its partner’s acute pancreatitis therapy, SCM-AGH and SCM-CGH, for chronic graft versus host disease through subsidiary CHA BioLab.Last October, the U
The pharmaceutical industry’s attention to CAR-T (chimeric antigen receptor T-cell) treatment is hotter than ever.The regulatory approval for Novartis’ CAR-T therapy Kymriah on March 5 fueled the anticipation for a new local CAR-T therapy market. Kymriah won the FDA’s nod in 2017, becoming the world
Samsung Biologics said Friday that the company would aim at the stable operation of its production facilities to provide one-stop service as contract development organization (CDO), contract research organization (CRO), and contract manufacturing organization (CMO).At a general shareholders’ meeting
An immunological correlate of protection (ICP) has emerged as the key to developing a Covid-19 vaccine among local vaccine developers.ICP is a biological indicator that indirectly measures the vaccine's effectiveness against infectious disease. Through ICP, researchers can evaluate the efficacy of a
Prestige Biopharma went public last month and announced that it would enter the vaccine market. The biosimilar and antibody-drug developer said it would build a vaccine manufacturing center to fight infectious diseases, including Covid-19.However, the Singapore-based company has not provided any det
SK Bioscience said that it has set about to develop a vaccine to cope with Covid-19 variants with financial support from the Coalition for Epidemic Preparedness Innovations (CEPI), an international private organization.The Korean company will receive up to $14.2 million (about 16 billion won) in res
The biotech industry is increasingly taking shareholder-friendly policies, with Alteogen, Seegene, and Hugel newly announcing to offer bonus shares and stock buybacks.Earlier last month, Macrogen decided to provide cash dividends for the first time in the company’s history. Dongkoo Bio & Pharma and
Theragen Bio said Wednesday it has acquired a patent for an immunogen-predicting algorithm, a key technology for developing vaccines to prevent the spread of new infectious diseases, such as Covid-19.The patent, called the “Computer program for predicting immunogen-predicting in treating viruses,” i
Celltrion is attempting to launch Regkirona (ingredient: Regdanvimab), its antibody treatment for Covid-19, in global markets, including the U.S. and EU.As the European Medicines Agency (EMA) has initiated a full-fledged review of the treatment, the Korean industry keeps a keen eye on the results Ce
A lawmaker said Celltrion has given up the clinical trials of a Covid-19 prevention antibody treatment, which the company had planned to carry out after launching Regkirona (ingredient: Regdanvimab), the first home-grown Covid-19 treatment.According to Rep. Jeon Bong-min, an independent lawmaker, Ce
The Korea Biotechnology Industry Organization (Korea BIO) will go all out to strengthen domestic bioindustry global competitiveness by organizing investment relations (IR) events for startups and conducting various foreign exchange programs, its new leader said Wednesday.“To enhance further the inte
Tego Science said on Wednesday it has completed the enrollment of patients for a phase-3 clinical trial of TPX-114, an autologous cell therapy.TPX-114 is an autologous cell therapy that treats full-thickness rotator cuff tear using the patient’s tissues. The company will secure efficacy data from th
SK Bioscience said Tuesday that it would expand its contract manufacturing business on top of the existing platform technologies for various vaccines under development on the occasion of initial public offering early next month.In a news conference, CEO Ahn Jae-yong said that the company has recentl
Celltrion said Tuesday that it attained sales of 1.84 trillion won ($1.65 billion) and an operating profit of 712.1 billion won last year, recording a business profit rate of 38.5 percent.Celltrion’s 2020 sales and operating profits registered growth rates of 63.9 percent and 8.4 percent from 2019,
Pharmicell said four seriously ill Covid-19 patients recovered after receiving its allogeneic mesenchymal stem cell therapy, Cellgram-AKI, over the past year.The company said it would continue working on the investigational drug to treat Covid-19.Pharmicell initially developed Cellgram-AKI as a stem